Announcement on Early Termination of GV-971 Global Multi-Center Phase III Clinical Trial

Green Valley Obtains IND Approval from U.S. FDA for Sodium Oligomannate’s Global Phase II Clinical Trial in Treating Parkinson’s Disease

GV-971 Gets Included in China National Reimbursement Drug List

GV-971 Global Phase III Clinical Trial Completes First Patient Dosed in Greater China

GV-971 Global Phase III Clinical Trial Officially Initiates in Greater China

GV-971 Global Phase III Clinical Trial Completes First Patient Dosed Globally

GV-971 Global Multi-center Phase III Clinical Trial Kicks-off Patient Enrollment Process

Green Valley Obtains IND Approval from U.S. FDA for Sodium Oligomannate’s International, Phase III Clinical Study